Recruiting A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 Conditions ALK Genomic Tumor Aberrations, Adenocarcinoma, Adenoma, +69 more Locations University of Colorado Cancer Center — Aurora, Colorado, United States Florida Cancer Specialists — Lake Mary, Florida, United States Dartmouth Hitchcock — Lebanon, New Hampshire, United States Brown University Health Cancer Institute — Providence, Rhode Island, United States View more locations Show fewer locations Loading locations... View Trial Details
Recruiting 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962 Conditions Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +46 more Locations Nepean Hospital — Kingswood, New South Wales, Australia Wollongong Hospital — Wollongong, New South Wales, Australia Gold Coast University Hospital — Southport, Queensland, Australia Cancer Research SA (CRSA) — Adelaide, South Australia, Australia View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042 Conditions Adenocarcinoma, Breast Diseases, Breast Neoplasms, +43 more Locations HonorHealth Research Institute — Scottsdale, Arizona, United States Sarah Cannon Research Institute at HealthONE — Denver, Colorado, United States Yale Cancer Center — New Haven, Connecticut, United States Moffitt Cancer Center — Tampa, Florida, United States View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders NCT05286294 Conditions Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +39 more Locations Oslo University Hospital — Oslo, Norway View Trial Details
